The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
Open accessAbstract
Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and adolescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We find PAX3–FOXO1 reprograms the cis-regulatory landscape by inducing de novo super enhancers. PAX3–FOXO1 uses super enhancers to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3–FOXO1-occupied super enhancers. Furthermore, PAX3–FOXO1 recruits and requires the BET bromodomain protein BRD4 to function at super enhancers, resulting in a complete dependence on BRD4 and a significant susceptibility to BRD inhibition. These results yield insights into the epigenetic functions of PAX3–FOXO1 and reveal a specific vulnerability that can be exploited for precision therapy. Significance: PAX3–FOXO1 drives pediatric fusion-positive rhabdomyosarcoma, and its chromatin-level functions are critical to understanding its oncogenic activity. We find that PAX3–FOXO1 establishes a myoblastic super enhancer landscape and creates a profound subtype-unique dependence on BET bromodomains, the inhibition of which ablates PAX3–FOXO1 function, providing a mechanistic rationale for exploring BET inhibitors for patients bearing PAX-fusion rhabdomyosarcoma. Cancer Discov; 7(8); 884–99. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 783
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
Rao, S. S. P., Huntley, M. H., Durand, N. C., Stamenova, E. K., Bochkov, I. D., Robinson, J. T., Sanborn, A. L., Machol, I., Omer, A. D., Lander, E. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.021 · Cited by 9,212
Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N. J., Livak, K. J., Mikkelsen, T. S., & Rinn, J. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2859 · Cited by 7,314
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845 · cited 1×
“ChIP-seq and RNA-seq ChIP-seq (59) and RNA-seq (3) were performed as previously described.”
MethodSelf-citationIntegrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
GREAT improves functional interpretation of cis-regulatory regions
McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M., & Bejerano, G. (2010) · Nature Biotechnology · doi:10.1038/nbt.1630 · Cited by 4,502
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“Of note, FP-RMS was sensitive to inhibiton of BRD4 (36), which has recently shown promising results in RMS tumor models (13), although no molecular explanation in connection with PAX3–FOXO1 has previously been made.”
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“Super Enhancer Analysis in RMS Cell Lines and Primary Tumors Implicates MYOD, MYOG, and MYCN as Master Regulators A small fraction of active enhancers acquire a large fraction of transcriptional machinery and active chromatin marks (frequently demarcated by H3K27ac), and have been defined as super enhancers (22, 23).”
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Mapping and analysis of chromatin state dynamics in nine human cell types
Ernst, J., Kheradpour, P., Mikkelsen, T. S., Shoresh, N., Ward, L. D., Epstein, C. B., Zhang, X., Wang, L., Issner, R., Coyne, M., et al. (2011) · Nature · doi:10.1038/nature09906 · Cited by 2,898
Self-citationBET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Transcriptional Regulation and Its Misregulation in Disease
Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.014 · Cited by 1,620
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., Tessarollo, L., Casellas, R., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.033 · Cited by 1,075
Self-citationTherapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 878
Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M., Ambrogio, L., Auclair, D., Wang, J., Song, Y. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0639 · Cited by 756
Self-citationChapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · cited 3×
“Our data adds to the pleiotropic utility of BRD4 inhibitors, with a recent wave of studies in a diverse group of cancers (37, 46-50).”
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma
Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., & Emanuel, B. S. (1993) · Nature Genetics · doi:10.1038/ng0293-113 · Cited by 555
Self-citationQuantitative ChIP-Seq normalization reveals global modulation of the epigenome
Orlando, D. A., Chen, M. W., Brown, V. E., Solanki, S., Choi, Y. J., Olson, E. R., Fritz, C. C., Bradner, J. E., & Guenther, M. G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.018 · Cited by 503
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
Kadoch, C., & Crabtree, G. R. (2013) · Cell · doi:10.1016/j.cell.2013.02.036 · Cited by 484
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake
Kitamura, T., Feng, Y., Ido Kitamura, Y., Chua, S. C., Xu, A. W., Barsh, G. S., Rossetti, L., & Accili, D. (2006) · Nature Medicine · doi:10.1038/nm1392 · Cited by 446
Riggi, N., Knoechel, B., Gillespie, S. M., Rheinbay, E., Boulay, G., Suvà, M. L., Rossetti, N. E., Boonseng, W. E., Oksuz, O., Cook, E. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.004 · Cited by 445
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Khan, J. I., Simon, R., Bittner, M. L., Chen, Y., Leighton, S. B., Pohida, T. J., Smith, P. D., Jiang, Y. Y., Gooden, G. C., Trent, J. M., et al. (1998) · PubMed · Cited by 437
Self-citationActive medulloblastoma enhancers reveal subgroup-specific cellular origins
Lin, C. Y., Erkek, S., Tong, Y., Yin, L., Federation, A. J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.-J., et al. (2016) · Nature · doi:10.1038/nature16546 · Cited by 380
Missiaglia, E., Williamson, D., Chisholm, J., Wirapati, P., Pierron, G., Petel, F., Concordet, J.-P., Thway, K., Oberlin, O., Pritchard-Jones, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5591 · Cited by 365
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Roe, J.-S., Mercan, F., Rivera, K., Pappin, D. J., & Vakoc, C. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.011 · Cited by 337
Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples
Jin, W., Tang, Q., Wan, M., Cui, K., Zhang, Y., Ren, G., Ni, B., Sklar, J., Przytycka, T. M., Childs, R., et al. (2015) · Nature · doi:10.1038/nature15740 · Cited by 332
Self-citationLockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
Khan, J., Bittner, M. L., Saal, L. H., Teichmann, U., Azorsa, D. O., Gooden, G. C., Pavan, W. J., Trent, J. M., & Meltzer, P. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13264 · Cited by 314
Self-citationDavicioni, E., Graf Finckenstein, F., Shahbazian, V., Buckley, J. D., Triche, T. J., & Anderson, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4578 · Cited by 308
Models of human core transcriptional regulatory circuitries
Saint-André, V., Federation, A. J., Lin, C. Y., Abraham, B. J., Reddy, J., Lee, T. I., Bradner, J. E., & Young, R. A. (2016) · Genome Research · doi:10.1101/gr.197590.115 · Cited by 298
Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma
Chen, X., Stewart, E., Shelat, A. A., Qu, C., Bahrami, A., Hatley, M., Wu, G., Bradley, C., McEvoy, J., Pappo, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.002 · Cited by 294
Cao, L., Yu, Y., Bilke, S., Walker, R. L., Mayeenuddin, L. H., Azorsa, D. O., Yang, F., Pineda, M., Helman, L. J., & Meltzer, P. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0582 · Cited by 239
Applications of chemogenomic library screening in drug discovery
Jones, L. H., & Bunnage, M. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.244 · Cited by 188
PAX3–FOXO1 fusion gene in rhabdomyosarcoma
Linardic, C. M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.035 · Cited by 175
Davis, R. J., & Barr, F. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8047 · Cited by 156
Self-citationMuscling in: Uncovering the origins of rhabdomyosarcoma
Hettmer, S., & Wagers, A. J. (2010) · Nature Medicine · doi:10.1038/nm0210-171 · Cited by 151
Lineage of origin in rhabdomyosarcoma informs pharmacological response
Abraham, J., Núñez‐Álvarez, Y., Hettmer, S., Carrió, E., Chen, H.-I. H., Nishijo, K., Huang, E., Prajapati, S. I., Walker, R. L., Davis, S. R., et al. (2014) · Genes & Development · doi:10.1101/gad.238733.114 · Cited by 117
Chang, W., Brohl, A. S., Patidar, R., Sindiri, S., Shern, J. F., Wei, J. S., Song, Y., Yohe, M. E., Gryder, B. E., Zhang, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2717 · Cited by 117
Self-citationThe Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Bid, H. K., Phelps, D. A., Xaio, L., Guttridge, D. C., Lin, J., London, C. A., Baker, L. H., Mo, X. M., & Houghton, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0567 · Cited by 101
Crose, L. E. S., Etheridge, K. T., Chen, C., Belyea, B., Talbot, L. J., Bentley, R. C., & Linardic, C. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3063 · Cited by 94
The Role of IGF-1R in Pediatric Malignancies
Kim, S. Y., Toretsky, J. A., Scher, D., & Helman, L. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0189 · Cited by 90
Stewart, E. A., Federico, S. M., Karlström, Å., Shelat, A. A., Sablauer, A., Pappo, A. S., & Dyer, M. A. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.03.001 · Cited by 84
Is a super-enhancer greater than the sum of its parts?
Dukler, N., Gulko, B., Huang, Y.-F., & Siepel, A. (2017) · Nature Genetics · doi:10.1038/ng.3759 · Cited by 79
Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma
Tenente, I. M., Hayes, M. N., Ignatius, M. S., McCarthy, K. M., Yohe, M. E., Sindiri, S., Gryder, B. E., Oliveira, M. L., Ramakrishnan, A., Tang, Q., et al. (2017) · eLife · doi:10.7554/elife.19214 · Cited by 79
Self-citationKutko, M. C., Glick, R. D., Butler, L. M., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2003) · PubMed · Cited by 63
Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR
Begum, S., Emani, N., Cheung, A., Wilkins, O., Der, S., & Hamel, P. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208315 · Cited by 62
Cited by
Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Self-citationAdvances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
McBride, M. J., Pulice, J. L., Beird, H. C., Ingram, D. R., D’Avino, A. R., Shern, J. F., Charville, G. W., Hornick, J. L., Nakayama, R. T., Garcia-Rivera, E. M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.002 · Cited by 273
Self-citationPeneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., Sheffield, N. C., Pierron, G., Lapouble, E., Tötzl, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23445-w · Cited by 200
Metadata
- Authors
- Gryder, B. E., Yohe, M. E., Chou, H.-C., Zhang, X., Marques, J., Wachtel, M., Schaefer, B., Sen, N., Song, Y., Gualtieri, A., Pomella, S., Rota, R., Cleveland, A., Wen, X., Sindiri, S., Wei, J. S., Barr, F. G., Das, S., Andresson, T., Guha, R., Lal-Nag, M., Ferrer, M., Shern, J. F., Zhao, K., Thomas, C. J., & Khan, J.
- Venue
- Cancer Discovery
- Published
- 2017-08-01
- Volume
- 7
- Issue
- 8
- Pages
- 884-899
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2609598144
- Cited by
- 316
- References
- 58
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.